Best Practice & Research Clinical Haematology

Papers
(The TQCC of Best Practice & Research Clinical Haematology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Contemporary and future strategies in polycythemia vera75
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation37
The role of randomized controlled trials, registries, observational databases in evaluating new interventions35
Coagulopathy in COVID-19 and anticoagulation clinical trials32
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program28
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)25
Endpoint selection and evaluation in hematology studies24
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes24
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances22
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL20
Editorial Board20
The presentation of results from studies in clinical haematology18
Targeted cellular therapy for treatment of relapsed or refractory leukemia14
Take a spin: Apheresis in the care of adult leukaemia patients14
Vaccine-induced immune thrombotic thrombocytopenia12
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma11
Creating a GMP cell processing program: A focus on quality and regulation11
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults10
Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma10
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms10
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”10
The international cooperative Gaucher group (ICCG) Gaucher registry10
Accelerated and blast phase myeloproliferative neoplasms10
Principles of cost-effectiveness studies and their use in haematology10
What should be done and what should be avoided when comparing two treatments?10
Dysregulation of Protein S in COVID-199
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders8
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration8
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma8
Editorial Board8
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?7
Handling missing covariate data in clinical studies in haematology7
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment7
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation7
Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025]7
The role of registries in hematological disorders7
Anti-GM-CSF autoantibodies in myeloid leukemias7
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies7
Addressing symptom burden in myeloproliferative neoplasms7
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia6
A reflection on Arnold Caplan, the father of MSC6
Recent progress in acute leukemia and myelodysplasia6
Editorial Board / Aims & Scope6
Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479]6
Cytokines in hematopoietic cell transplantation and related cellular therapies6
CAR assembly line: Taking CAR T-cell manufacturing to the next level6
0.14661407470703